Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 07h00 HE
|
Annovis Bio, Inc.
BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
27 avr. 2023 07h00 HE
|
Annovis Bio, Inc.
BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
11 mars 2021 07h05 HE
|
Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
31 janv. 2020 11h46 HE
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative...
Annovis Bio Announces Pricing of Initial Public Offering
28 janv. 2020 23h31 HE
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the...
Annovis Appoints Jeffrey McGroarty Chief Financial Officer
09 juil. 2019 08h45 HE
|
Annovis Bio, Inc.
BERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...
QR Pharma Adopts new Corporate Name: Annovis Bio
24 juin 2019 13h30 HE
|
Annovis Bio, Inc.
BERWYN, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- QR Pharma, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...